Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
复制标题
DOI：
10.1111/j.1463-1326.2008.00880.x
复制
发表时间：
2008-12
期刊：
影响因子：
7.7
通讯作者：
Y. Miyazaki;R. DeFronzo
中科院分区：
文献类型：
--
作者：
Y. Miyazaki;R. DeFronzo
目的：观察罗格列酮治疗对2型糖尿病(T2 DM)患者脂肪细胞因子水平、餐后胰岛素及血糖、血脂水平的影响，并与吡格列酮治疗进行比较。
Objective: We examined the effects of rosiglitazone treatment on profiles of adipocytokines levels, postprandial insulin and glucose excursion, lipids levels, comparing with those of pioglitazone treatment in patients with type 2 diabetes mellitus (T2DM).